Measurement of posaconazole, itraconazole, and hydroxyitraconazole in plasma/serum by high-performance liquid chromatography with fluorescence detection

Therapeutic Drug Monitoring

Volumn 33, Issue 6, 2011, Pages 735-741

  Buckner, Sara L ^a   Ceesay, M Mansour ^b   Pagliuca, Antonio ^b   Morgan, Phillip E ^a   Flanagan, Robert J ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Fluorescence; HPLC; Itraconazole; Posaconazole; Therapeutic drug monitoring

Indexed keywords

HYDROXYITRACONAZOLE; ITRACONAZOLE; POSACONAZOLE;

ACCURACY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; FLUORESCENCE ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INVASIVE ASPERGILLOSIS; MALE; PLASMA; PRIORITY JOURNAL; QUALITY CONTROL; SERUM;

ADULT; AGED; ANTIFUNGAL AGENTS; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; HUMANS; INVASIVE PULMONARY ASPERGILLOSIS; ITRACONAZOLE; LIMIT OF DETECTION; MALE; MIDDLE AGED; NEUTROPENIA; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, FLUORESCENCE; TRIAZOLES; YOUNG ADULT;

EID: 84856111094     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3182381bb1     Document Type: Article

References (35)

1. Bow E, Loewen R, Cheang M, et al. Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukaemia: the pathogenic role of the antileukaemic regimen. Clin Infect Dis. 1995;21:361-369.
2. Bow E. Infection risk and cancer chemotherapy: the impact of the chemotherapeutic regimen in patients with lymphoma and solid tissue malignancies. Antimicrob Agents Ch. 1998;41:1-5. (Pubitemid 28284501)
3. Cornely O, Böhme A, Buchheidt D, et al. Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies. Haematologica. 2009;94:113-122.
4. Maertens J. Evaluating prophylaxis if invasive fungal infections in patients with haematological malignancies. Eur J Haematol. 2007;78:275-282. (Pubitemid 46365078)
5. Groll A, De Lucca A, Walsh T. Emerging targets for the development of novel antifungal therapeutics. Trends Microbiol. 1998;6:117-124. (Pubitemid 28123332)
6. Heimark L, Shipkova P, Greene J, et al. Mechanism of azole antifungal activity as determined by liquid chromatographic/mass spectrometric monitoring of ergosterol biosynthesis. J Mass Spectrom. 2002;37:265-269. (Pubitemid 34240312)
7. Greenberg RN, Mullane K, van Burik JAH, et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Ch. 2006;50:126-133. (Pubitemid 43042912)
8. Lewis RE. Pharmacokinetic-pharmacodynamic optimization of triazole antifungal therapy. Curr Opin Infect Dis. 2011;24:S14-S29.
9. Cunliffe JM, Noren CF, Hayes RN, et al. A high-throughput LC-MS/MS method for the quantitation of posaconazole in human plasma: implementing fused core silica liquid chromatography. J Pharmaceut Biomed. 2009;50:46-52.
10. Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Ch. 2009;53:24-34.
11. Hope W, Billaud E, Lestner J, et al. Therapeutic drug monitoring for triazoles. Curr Opin Infect Dis. 2008;21:580-586.
12. Lestner J, Roberts S, Moore C, et al. Toxicodynamics of itraconazole: implications for therapeutic drug Monitoring. Clin Infect Dis. 2009;49:928-930.
13. Smith J, Andes D. Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. Ther Drug Monit. 2008;30:167-172. (Pubitemid 351521643)
14. Willems L, van der Geest R, de Beule K. Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics. J Clin Pharm Ther. 2001;26:159-169. (Pubitemid 32592545)
15. Wang E, Lew K, Casciano N, et al. Interaction of common azole antifungals with P glycoprotein. Antimicrob Agents Ch. 2002;46:160-165. (Pubitemid 34031618)
16. Ullmann A, Cornely O, Burchardt A, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Ch. 2006;50:658-666. (Pubitemid 43190980)
17. Gubbins P, Krishna G, Sansone-Parsons A, et al. Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients. Antimicrob Agents Ch. 2006;50:1993-1999. (Pubitemid 43807517)
18. Krishna G, Martinho M, Chandrasekar P, et al. Pharmacokinetics of oral posaconazole in allogenic haematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy. 2007;27:1627-1636. (Pubitemid 350234311)
19. Kohl V, Muller C, Cornely O, et al. Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing stem cell transplantation. Antimicrob Agents Ch. 2010;54:207-212.
20. Alfenaar JWC, Wessels AMA, van Hateren K, et al. Method for therapeutic drug monitoring of azole antifungal drugs in human serum using LC/MS/MS. J Chromatogr B. 2010;878:39-44.
21. Chahbouni A, Wilhelm AJ, den Burger JCG, et al. Validated liquid chromatography-tandem mass spectroscopy method for the simultaneous quantification of four antimycotic agents in human serum. Ther Drug Monit. 2010;32:453-457.
22. Gordien J-B, Pigneux A, Vigouroux S, et al. Simultaneous determination of five systemic azoles in plasma by high-performance liquid chromatography with ultraviolet detection. J Pharmaceut Biomed. 2009;50:932-938.
23. Guidance for industry. Bioanalytical method validation. FDA/CDER. 2001. Available at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf. Accessed March 31, 2011.
24. Isoherranen N, Kunze KL, Allen KE, et al. Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab Dispos. 2004;32:1121-1131. (Pubitemid 39287586)
25. de Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813-1821.
26. Boogaerts M, Verhoef G, Zachee P, et al. Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Mycoses. 1989;32:103-108. (Pubitemid 20118620)
27. Glasmacher A, Hahn C, Leutner C, et al. Breakthrough invasive fungal infections in patients after prophylaxis with itraconazole. Mycoses. 1999;42:443-451. (Pubitemid 29470385)
28. Hardin T, Graybill J, Fetchick R, et al. Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Ch. 1988;32:1310-1313.
29. Posaconazole. FDA briefing document. 2009. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2006/022003s000-Noxafil- ClinPharmR.pdf. Accessed March 31, 2011.
30. Thomson G, Rinaldi M, Patterson T, et al. Posaconazole therapeutic drug monitoring: a reference laboratory experience. Antimicrob Agents Ch. 2009;53:2223-2224.
31. Lebeaux D, Lanternier F, Elie C, et al. Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults. Antimicrob Agents Ch. 2009;53:5224-5229.
32. Courtney R, Radwanski E, Lim J, et al. Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob Agents Ch. 2004;48:804-808. (Pubitemid 38280328)
33. Krishna G, Moton A, Ma L, et al. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Ch. 2009;53:958-966.
34. Gubbins PO, Krishna G, Sansone-Parsons A, et al. Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients. Antimicrob Agents Ch. 2006;50:1993-1999. (Pubitemid 43807517)
35. Ullmann AJ, Cornely OA, Burchardt A, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Ch. 2006;50:658-666. (Pubitemid 43190980)